Ovarian cancer. Malignant neoplasm of ovary
Conditions
Interventions
Intervention 1: In the study group, a 500mg daily dose of metformin was started (gradually increasing to 1500 mg daily divided three times a day within a week) in addition to standard carboplatin-pacl
Treatment - Drugs
In the study group, a 500mg daily dose of metformin was started (gradually increasing to 1500 mg daily divided three times a day within a week) in addition to standard carboplatin-paclitaxel regimen
The control group receives standard chemotherapy regimen.in stage 1 or 2 of cancer they recieved 3-6 courses of carboplatin-paclitaxel regimen chemotherapy while patients in stage 3 or 4 recieved 6-9
Sponsors
Vice chancellor of research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
30 Years to 80 Years
Inclusion criteria
Inclusion criteria: all women with histopathologic diagnosis of epithelial ovarian carcinoma undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy in shahid faghihi hospital(shiraz)march 2011 to march 2015 were included. those with the following criteria were excluded from the study: diabetic patients; patients with liver or gastrointestinal disorders or renal failure; patients unable to tolerate metformin; patients who received neoadjuvant chemotherapy before cytoreductive surgery; patients whose ovarian cancer is secondary to other cancers
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 year recurrence rate. Timepoint: 2 years. Method of measurement: Visit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival. Timepoint: 2-4 years. Method of measurement: Visit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShohreh Roozmeh
Shiraz University of Medical Sciences
Outcome results
None listed